White papers by Friends address external controls, progression on immunotherapy, companion diagnostics November 15, 2019Vol.45 No.43By Matthew Bin Han Ong
Conversation with The Cancer Letter Teitell: How immunotherapy became the fourth pillar of cancer care at UCLA November 15, 2019Vol.45 No.43By Paul Goldberg
Conversation with The Cancer LetterFree U.S. Nobel laureates tell us what they think about cancer research, moonshots, the dark side, funding, meritocracy, herd mentality, Trump, and joy November 15, 2019Vol.45 No.43By Alexandria Carolan
FreeTrials & Tribulations Major gaps persist in Americans’ knowledge of and actions on cancer prevention November 08, 2019Vol.45 No.42By Howard A. "Skip" Burris III
FDA Office of Hematology and Oncology Products is now Office of Oncologic Diseases November 08, 2019Vol.45 No.42By Matthew Bin Han Ong
Sharpless returns to NCI; Hahn to be nominated FDA commissioner; Giroir assumes acting role November 08, 2019Vol.45 No.42By Alexandria Carolan
Texas votes to keep CPRIT open with another $3 billion in state funding November 08, 2019Vol.45 No.42By Matthew Bin Han Ong
Conversation with The Cancer Letter Purdue’s Thompson: Lomustine establishes proof of principle for resolving cancer drug shortages November 08, 2019Vol.45 No.42By Paul Goldberg
Lomustine’s path from unavailable but cheap to plentiful but expensiveNeeded: A better manufacturing method November 08, 2019Vol.45 No.42By Paul Goldberg
Free Sharpless to return to NCI as Hahn gets nominated as FDA commissioner, with Giroir to serve as acting November 01, 2019Vol.45 No.41By Alexandria Carolan
